Jardiance Cost in North Dakota 2026: Cash Price, Insurance, Medicaid & Compounded Options

What Is the Retail Cash Price of Jardiance in North Dakota in 2026?

The average cash price for Jardiance at North Dakota retail pharmacies in 2026 is approximately $680 per month for a 30-tablet supply at either the 10 mg or 25 mg dose. This figure reflects the Boehringer Ingelheim and Eli Lilly manufacturer list price and does not account for coupons, savings cards, or insurance negotiated rates. Prices can shift by $20 to $40 depending on the pharmacy chain, so calling ahead to compare is worth the few minutes it takes.

No FDA-approved generic empagliflozin was on the market as of the first half of 2025. Patent expiry timelines for Jardiance are contested in ongoing litigation, so a low-cost generic is unlikely to arrive before 2025 to 2026 patent resolution. The FDA maintains the current labeling and approval status on its drug database; you can verify the most recent label at the Jardiance FDA label page.

Empagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It blocks glucose reabsorption in the proximal tubule of the kidney, producing glycosuria and modest caloric loss. In EMPA-REG OUTCOME (N=7,020 patients with type 2 diabetes and established cardiovascular disease), empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) [1]. That cardiovascular mortality signal makes pricing and access genuinely consequential for North Dakota patients who carry comorbid heart disease.

Does North Dakota Medicaid Cover Jardiance?

North Dakota Medicaid does not cover Jardiance (empagliflozin) for most enrollees under the current preferred drug list (PDL). Medicaid managed care and fee-for-service plans in the state generally tier SGLT2 inhibitors as non-preferred or excluded, requiring prior authorization that is frequently denied without documented failure of metformin and one to two additional agents.

The practical effect: a patient who qualifies for North Dakota Medicaid based on income cannot rely on Medicaid as a payment pathway for Jardiance without a successful prior authorization appeal or a physician-documented exception. The North Dakota Department of Human Services Pharmacy Program publishes the PDL quarterly; checking the most recent version before submitting a prior authorization saves time.

For patients with CKD or heart failure, the clinical argument for coverage is stronger because the FDA-approved CKD indication (approved July 2023) and the HFpEF indication carry dedicated trial evidence. EMPEROR-Reduced (N=3,730) showed a 25% reduction in the composite of cardiovascular death or hospitalization for heart failure versus placebo (HR 0.75; 95% CI 0.65 to 0.86; P<0.001) [2]. Citing EMPEROR-Reduced data directly in a Medicaid prior authorization letter may improve approval rates for qualifying heart failure patients.

Medicare Part D plans in North Dakota operate separately from Medicaid. Several Part D formularies do include Jardiance, typically on Tier 3 or Tier 4, with copays ranging from $45 to $180 per month after the deductible phase. The CMS Medicare Plan Finder lets patients enter their zip code and medication list to compare specific plan costs for 2026.

Which Commercial Insurance Plans Cover Jardiance in North Dakota?

Most large commercial insurers operating in North Dakota include empagliflozin on their formularies, though tier placement and required prior authorization steps vary by plan. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica all list Jardiance in their 2025 to 2026 formularies, generally at Tier 3 specialty. Typical commercial cost-sharing after the deductible runs $60 to $150 per month.

Prior authorization is common. Insurers typically require documentation of an HbA1c above a specified threshold (often 7.5% or higher), evidence that metformin was trialed and either was ineffective or caused contraindicated side effects, and a confirmed diagnosis matching an FDA-approved indication. For heart failure or CKD indications, documentation of an echocardiogram or eGFR measurement below 45 mL/min/1.73m2 may be required.

Step therapy protocols can delay access by 30 to 90 days. Patients who need Jardiance urgently due to a heart failure hospitalization should ask their prescriber to request a step-therapy exception under the North Dakota Health Insurance Mandates law, which allows such exceptions for certain established-evidence conditions.

The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and established or high risk for cardiovascular disease, heart failure, or chronic kidney disease, an SGLT2 inhibitor with proven cardiovascular or renal benefit is recommended independent of baseline HbA1c" [3]. This guideline language can be quoted directly in prior authorization appeals.

How Does the Boehringer Ingelheim and Lilly Savings Card Work in North Dakota?

Commercially insured patients in North Dakota who are not enrolled in a federal or state government health program can use the Jardiance Savings Card from Boehringer Ingelheim and Eli Lilly. The card reduces out-of-pocket cost to as low as $10 per month for eligible patients, with a cap of $150 per fill and an annual benefit maximum that Boehringer Ingelheim has periodically adjusted.

Eligibility rules are strict. Patients on Medicare, Medicaid, Medicaid Managed Care, CHIP, or any other government-funded program are explicitly excluded. A patient who ages into Medicare mid-year must stop using the savings card at that point or risk violating program terms.

To activate the card, patients visit the Jardiance website or ask their pharmacist to apply the card at the point of sale. The card works at most major pharmacy chains in North Dakota including Walmart, Walgreens, CVS, and independent pharmacies that participate in the BIN/PCN network printed on the card. Processing failures sometimes occur at smaller independent pharmacies; calling the number on the card resolves most issues within minutes.

The savings card does not reduce the insurer's list price negotiation. It functions as a copay subsidy. Critics of this structure note that it may keep patients anchored to brand Jardiance rather than switching to a potentially cheaper alternative if a generic eventually arrives.

The HealthRX cost-reduction decision framework for North Dakota Jardiance patients works as follows. Step 1: confirm insurance status (commercial vs. Medicare vs. Medicaid vs. uninsured). Step 2: if commercially insured, apply the Boehringer Ingelheim savings card first before exploring any other pathway. Step 3: if on Medicare Part D, compare plans during open enrollment using the CMS Plan Finder and look for Extra Help eligibility if income is below 150% of the federal poverty level. Step 4: if on Medicaid or uninsured, request a 503A compounded empagliflozin prescription from a licensed North Dakota or out-of-state 503A pharmacy. Step 5: if cost remains prohibitive, ask the prescribing clinician to submit a Boehringer Ingelheim patient assistance program (PAP) application, which can provide free medication for patients with household income below 400% of the federal poverty level.

Is Compounded Empagliflozin Legal in North Dakota?

Compounded empagliflozin prepared by a state-licensed 503A pharmacy is legal in North Dakota as of mid-2025, provided the prescription is patient-specific and written by a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding and permits compounding of drugs that are not commercially available in the exact form, strength, or combination needed by the patient, or when a patient-specific medical need justifies deviation from the commercially available product.

North Dakota Board of Pharmacy rules align with federal 503A requirements. A compounding pharmacy physically located in another state can ship to North Dakota patients so long as the out-of-state pharmacy holds a valid non-resident pharmacy permit issued by the North Dakota Board of Pharmacy.

The cost difference can be significant. Some 503A pharmacies price compounded empagliflozin at $80 to $200 per month compared to the $680 brand price, depending on dose form, concentration, and the pharmacy's supply chain. Patients should confirm that the compounding pharmacy uses pharmaceutical-grade empagliflozin active pharmaceutical ingredient (API) and provides a certificate of analysis (COA) for each batch.

One important regulatory note: the FDA placed semaglutide and tirzepatide on the shortage list, permitting broader 503B outsourcing facility compounding for those drugs. Empagliflozin has not been placed on the FDA drug shortage list as of mid-2025, which means 503B outsourcing facilities cannot compound it in bulk for office stock. Only 503A pharmacies may compound it, and only with a valid patient-specific prescription.

The FDA's current guidance on compounding is available at FDA compounding pharmacy guidance. Patients considering compounded empagliflozin should ask their prescriber and pharmacy to confirm current regulatory status, because the FDA regularly updates its shortage list and policy guidance.

Can I Get a Jardiance Prescription via Telehealth in North Dakota?

Telehealth prescribing of Jardiance is permitted in North Dakota. State law does not require an in-person visit to establish a prescriber-patient relationship for most non-controlled medications, and empagliflozin is not a controlled substance. A licensed clinician in any state holding a North Dakota DEA registration or state prescribing license can prescribe Jardiance to a North Dakota resident via a synchronous audio-video visit.

North Dakota adopted telehealth parity rules that require most insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. The ND Century Code Section 26.1-36-09.18 specifies these parity requirements. Practically speaking, a patient in Bismarck, Minot, Fargo, or a rural county can connect with a board-certified endocrinologist or internist via a telehealth platform, receive an empagliflozin prescription, and have that prescription sent electronically to a local or mail-order pharmacy, all within one business day.

Telehealth is especially relevant for the 53% of North Dakota counties classified as rural or frontier, where access to endocrinology specialists is limited. The CDC Rural Health data documents that rural patients face an average of 40-plus miles of travel to reach a specialist, making telehealth a practical rather than merely convenient option.

What Are the FDA-Approved Indications for Empagliflozin?

The FDA has approved empagliflozin under the brand name Jardiance for four distinct indications, and understanding which one applies affects how a prior authorization is written. The four indications are:

Type 2 diabetes mellitus in adults, to improve glycemic control as an adjunct to diet and exercise. This was the original 2014 approval.

Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, based on EMPA-REG OUTCOME data showing a statistically significant reduction in cardiovascular mortality [1].

Heart failure in adults, covering both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The HFpEF approval (EMPEROR-Preserved trial, N=5,988) was notable because few therapies had demonstrated benefit in HFpEF before empagliflozin [4].

Chronic kidney disease (CKD) in adults at risk of CKD progression, based on the EMPA-KIDNEY trial (N=6,609), which showed a 28% reduction in the risk of kidney disease progression or cardiovascular death versus placebo (HR 0.72; 95% CI 0.64 to 0.82; P<0.001) [5].

Each indication opens a separate clinical justification for insurance coverage. A patient with type 2 diabetes and CKD can have both diagnoses listed on the prior authorization, strengthening the case.

What Clinical Evidence Supports Long-Term Use of Empagliflozin?

The evidence base for empagliflozin spans more than a decade of randomized trial data. EMPA-REG OUTCOME, published in the New England Journal of Medicine in 2015, was the first cardiovascular outcomes trial for any SGLT2 inhibitor to show superiority over placebo in patients with established cardiovascular disease [1]. The trial enrolled 7,020 patients across 42 countries and followed them for a median of 3.1 years.

EMPEROR-Reduced (N=3,730) and EMPEROR-Preserved (N=5,988) together established empagliflozin's role across the full spectrum of ejection fraction in heart failure. EMPA-KIDNEY extended the evidence to CKD patients, some of whom did not have type 2 diabetes, demonstrating renal protective effects independent of glycemic benefit [5].

The mechanism underlying cardiorenal protection is not fully resolved. Proposed pathways include reduction in cardiac preload and afterload through natriuresis and osmotic diuresis, reduction in epicardial adiposity, direct effects on myocardial ketone metabolism, and reduction in intraglomerular pressure. The NEJM original EMPA-REG OUTCOME publication remains the foundational citation for clinical decision-making and insurance appeals alike [1].

Safety data across trials show consistent patterns. Genital mycotic infections occur in roughly 5% to 10% of patients, more frequently in women. Diabetic ketoacidosis (DKA) is rare but can occur even with near-normal glucose levels (euglycemic DKA); patients should be counseled to hold empagliflozin 3 to 4 days before elective surgery or during prolonged fasting. Fournier's gangrene has been reported rarely. These safety signals are documented in the FDA-approved labeling FDA label.

Practical Steps to Reduce Your Jardiance Cost in North Dakota in 2026

Getting from the $680 list price to something affordable involves knowing which lever to pull first based on your specific situation.

Commercially insured patients should activate the Boehringer Ingelheim savings card before the first fill. The savings card is available at Jardiance.com and requires only a few minutes of online registration. Pharmacists can also look up the card's BIN and PCN numbers directly, so patients do not always need to carry a physical card.

Uninsured patients have three realistic routes. The first is the Boehringer Ingelheim Patient Assistance Program, which provides free medication for qualifying patients. The application requires proof of income, a valid prescription, and a signed form from the prescribing clinician. Processing typically takes 2 to 4 weeks. The second route is a licensed 503A compounding pharmacy, which can prepare empagliflozin at a fraction of brand cost. The third is GoodRx or similar pharmacy discount platforms, which have occasionally shown prices of $500 to $620 at specific North Dakota pharmacies, a modest discount from list but meaningful over 12 months.

Medicare Part D patients should run an annual plan comparison every October during open enrollment. The difference between plans for a Tier 3 specialty medication like Jardiance can exceed $1,000 per year. Patients with low income and limited assets should apply for the Medicare Extra Help program (Low Income Subsidy), which can reduce Part D copays to $4.50 to $11.20 per month for covered medications.

Medicaid patients facing a coverage denial should request a prior authorization, document the cardiovascular or renal indication clearly, and cite ADA 2024 Standards of Care guideline language directly in the appeal. If the appeal fails, a 503A compounded empagliflozin prescription is the most cost-effective legal alternative.

Every patient starting empagliflozin, regardless of payment pathway, should receive counseling on genital hygiene, DKA risk during illness or fasting, and the importance of reporting unusual perineal pain promptly. The FDA label specifies these counseling points and provides the clinical framework prescribers use at initiation.